DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Exjade (Deferasirox) - Published Studies


Exjade Related Published Studies

Well-designed clinical trials related to Exjade (Deferasirox)

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. [2012]

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. [2012]

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. [2011.09.20]

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. [2011.08]

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. [2011.07.28]

[Curative effects and safety of deferasirox in treatment of iron overload in children with beta-thalassemia major]. [2011.07]

Effect of deferasirox on iron absorption in a randomized, placebo-controlled, crossover study in a human model of acute supratherapeutic iron ingestion. [2011.07]

Deferasirox does not induce QT/QTc-prolongation in healthy subjects. [2009.05]

Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. [2008.10]

Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. [2008.08]

Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. [2008.06]

Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. [2008.04]

Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. [2008.02]

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. [2008]

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. [2007.05]

Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. [2006.12]

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. [2006.10]

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. [2006.07]

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. [2006.05.01]

Well-designed clinical trials possibly related to Exjade (Deferasirox)

Risk factors for mortality in patients with mucormycosis. [2012]

Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload. [2005]

Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. [2003.06]

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. [2003.05.10]

Other research related to Exjade (Deferasirox)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. [2014]

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. [2013]

Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy. [2011.11.20]

Importance of optimal dosing >/= 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with beta-thalassaemia. [2011.10]

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. [2011.10]

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. [2011.09]

The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major. [2011.09]

Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. [2011.07]

Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil. [2011.06]

Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. [2011.06]

Long-Term Efficacy of Deferasirox in Preventing Cardiovascular Complications in the Iron-Overloaded Gerbil. [2011.05.18]

Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. [2011.05]

Iron chelation adherence to deferoxamine and deferasirox in thalassemia. [2011.05]

Is deferasirox implicated in multiple organ failure in a patient with homozygous beta-thalassemia? [2011.05]

Chelation of cadmium by combining deferasirox and deferiprone in rats. [2011.05]

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. [2011.05]

Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months. [2011.05]

Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. [2011.04]

Reversible Fanconi syndrome in a pediatric patient on deferasirox. [2011.04]

The effects of deferasirox on renal, cardiac and hepatic iron load in patients with beta-thalassemia major: preliminary results. [2011.04]

Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient. [2011.03]

Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. [2011.03]

Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. [2011.03]

Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia. [2011]

A case of well-tolerated and safe deferasirox administration during the first trimester of a spontaneous pregnancy in an advanced maternal age thalassemic patient. [2011]

Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia. [2011]

Safety and efficacy of deferasirox in multitransfused Indian children with beta-thalassaemia major. [2011]

[A 3-year clinical trial of deferasirox in heavily iron-overloaded patients with Beta-thalassemia major.] [2010.12]

[Deferasirox--a new oral iron chelator--review]. [2010.10]

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients. [2010.09]

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. [2010.09]

Deferasirox for managing transfusional iron overload in people with sickle cell disease. [2010.08.04]

Deferasirox--current knowledge and future challenges. [2010.08]

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. [2010.07.29]

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. [2010.07]

Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. [2010.07]

Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. [2010.05]

Gastric ulcer in a child treated with deferasirox. [2010.04]

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. [2010.04]

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. [2010.03.25]

Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. [2010.03.15]

Deferasirox: oral, once daily iron chelator--an expert opinion. [2010.02]

The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. [2010.02]

Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. [2010.02]

Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. [2010.01]

Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. [2010]

Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI. [2010]

Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. [2010]

Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy. [2010]

A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea. [2009.11]

Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. [2009.11]

Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. [2009.09]

Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes. [2009.08]

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. [2009.07]

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. [2009.06]

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. [2009.06]

Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. [2009.05]

Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. [2009.05]

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. [2009.05]

Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. [2009.05]

Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study. [2009.04]

Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia. [2009.03]

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. [2009.01]

Deferasirox: an update. [2009]

Deferasirox (Exjade) for the treatment of iron overload. [2009]

Long-term efficacy and safety of deferasirox. [2008.12]

Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction. [2008.12]

Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. [2008.12]

Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. [2008.10]

Acute interstitial nephritis due to deferasirox: a case report. [2008.10]

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. [2008.09]

Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. [2008.09]

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. [2008.07]

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. [2008.06]

Clinical application of deferasirox: practical patient management. [2008.05]

Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. [2008.05]

Patient-Reported Outcomes of Deferasirox (Exjade(R), ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. Substudy of a Randomized Open-Label Phase II Trial. [2008.04.11]

Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. [2008.02]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017